Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
SAN FRANCISCO, May 02, 2018 -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018, after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).
Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 46778299#.
Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 46778299#
About FibroGen
FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), except in China, where a New Drug Application is currently under review by the China Food and Drug Administration (recently reformed as the State Drug Administration, or SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe, and expected to shortly enter Phase 2/3 development in China, for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact
FibroGen, Inc.
Karen L. Bergman
Vice President, Investor Relations and Corporate Communications
1 (415) 978-1433
[email protected]
